Britannia Life Sciences Inc.
BLSIF
$0.0666
-$0.0114-14.62%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.80M | 2.79M | 4.07M | 4.16M | 4.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.80M | 2.79M | 4.07M | 4.16M | 4.28M |
| Cost of Revenue | 1.09M | 1.03M | 1.03M | 953.80K | 928.60K |
| Gross Profit | 1.71M | 1.76M | 1.76M | 1.92M | 2.06M |
| SG&A Expenses | 1.67M | 1.70M | 1.70M | 1.72M | 2.05M |
| Depreciation & Amortization | 11.30K | 10.70K | 10.70K | 10.70K | 10.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.77M | 2.74M | 3.78M | 3.72M | 4.02M |
| Operating Income | 32.70K | 50.90K | 295.00K | 441.50K | 250.80K |
| Income Before Tax | -1.21M | -1.38M | -1.38M | -1.07M | 278.10K |
| Income Tax Expenses | 151.60K | 151.60K | 151.60K | 144.60K | 139.00K |
| Earnings from Continuing Operations | -1.36 | -1.53 | -1.53 | -1.22 | 0.14 |
| Earnings from Discontinued Operations | -- | 176.10K | 176.10K | 176.10K | 176.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -112.40K | -161.70K | -161.70K | 20.10K | 78.70K |
| Net Income | -1.47M | -1.51M | -5.90M | -5.40M | -3.99M |
| EBIT | 32.70K | 50.90K | 295.00K | 441.50K | 250.80K |
| EBITDA | 81.60K | 99.20K | 347.10K | 524.30K | 368.10K |
| EPS Basic | -0.01 | -0.01 | -0.04 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.04 | -0.03 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Average Diluted Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |